2.3 Clinical Trial Matching
“Tempus provides an unparalleled level of commitment and support in aligning all involved parties and streamlining the process, especially given the challenges of the COVID-19 pandemic. We ultimately met our target goal of activating our trial in just two weeks”
Dr. Julio Peguero, Director of Research, Oncology Consultants


Precision medicine has changed the clinical research landscape

50+ unique clinical trials targeting a wide array of biomarkers including FGFR, KEAP1, RET, NOTCH1, ESR1, and MET.

  1. Smart trial matching
    Each patient’s sequenced molecular data and clinical history are compared against each trial’s structured inclusion and exclusion criteria through our proprietary trial matching software and methods.
  2. Rapid site activation
    Tempus utilizes a standardized contract, rate card, feasibility process, informed consent form (ICF), and a central IRB along with a team of dedicated research liaisons to streamline activities for study start-up.
  3. Site activated in an average of 9 days.

Trial Matching at Tempus


Provider networks


Active oncologists


Tempus patients match

to a biomarker trial


patients were identified

for potential clinical trials

in our network


A new precision medicine approach to clinical trials

Tempus generates, organizes, and analyzes extensive amounts of data through our next-generation sequencing lab, AI-assisted clinical data structuring capabilities, and connectivity with researchers across the network. We support providers in identifying relevant and actionable clinical trials for their patients.

Our proprietary clinical trial matching software enables real-time matches for relevant, open, and recruiting clinical trials. Tempus’ team of trained abstractors manually reviews all protocol-specific inclusion and exclusion eligibility criteria for trials in the TIME Trial Program.

Request a Demo


Bringing the right clinical trial to the right patient in days instead of months

The program is designed to provide access to thousands of physicians and patients to clinical trials and novel therapeutics, no matter where they are.

All sites and sponsors participating in the TIME Trial Program commit to a standard clinical trial agreement, a pre-negotiated budget, and the use of a central IRB. Additionally, Tempus’ dedicated, expert research liaisons support sites and sponsors in streamlining all recruitment and enrollment activities

The entire activation process is designed to take 9 business days, and the site always makes the decision about particular studies for involvement.

  • Patient Identified
  • Day 0 Site notified of eligible patient
  • Day 3 Contract signed by site and sponsor
  • Day 7 IRB approved and study materials sent
  • Day 10 Site initiation and training
  • Day 14 Patient entrolled in open trial
“The current clinical trial process is cumbersome and inefficient. As treatments become more molecularly targeted, finding innovative ways to increase participation is key to therapeutic development and ultimately improved patient care. Having a TIME Trial model is visionary and the wave of the future. This model has the potential to bring innovative and novel therapies to a larger percentage of our patients.”
Dr. Michael P. Kosty, MD, FACP, FASCO, Director of Thoracic Oncology, Scripps/MD Anderson Cancer Center in La Jolla, CA.


The TIME Trial Program activates unique clinical trials targeting a range of biomarkers at Institutions across the United States.

Learn more about recent rapid activation success stories in our TIME Tech Spotlight.


Learn more about our rapid site activation technology.

  • This field is for validation purposes and should be left unchanged.